文献速递慢性肾脏病

肥胖作为肾脏病风险因素的治疗标准

Risk factor obesity: treatment standard.
PubMed 文献 · Nephrol Dial Transplant · 2026-01-01

本文综述肥胖作为慢性肾脏病(CKD)独立风险因素的病理生理机制与治疗标准。肥胖通过血流动力学、代谢和炎症通路导致肾损伤,包括肾小球高滤过、足细胞应激和脂毒性等。文章讨论新兴治疗选择(含incretin类药物)以预防疾病进展并降低心血管负担。

要点

  • 肥胖是CKD的直接独立风险因素,不依赖糖尿病和高血压。
  • 肾损伤机制涉及肾小球高滤过、足细胞应激、脂毒性和RAAS激活等。
  • 需关注新兴incretin类药物治疗以延缓CKD进展并降低心血管风险。

核心结论

  • 肥胖是CKD的直接独立风险因素,需重视其治疗以预防疾病进展和降低心血管负担。

研究设计与样本

  • 综述,旨在回顾肥胖作为肾损伤和CKD风险因素的当前治疗标准及新进展。

主要发现

  • 肥胖通过血流动力学、代谢和炎症通路促进肾损伤,包括肾小球高滤过、足细胞应激、脂毒性、胰岛素抵抗、RAAS激活和慢性低度炎症。

临床怎么用

  • 临床应将肥胖作为CKD独立风险因素管理,关注新兴incretin类疗法以延缓CKD进展并降低心血管风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Obesity is a global epidemic and is increasingly recognized as a direct and independent risk factor for chronic kidney disease (CKD), beyond its established associations with diabetes and hypertension. Excess adiposity promotes kidney injury through convergent hemodynamic, metabolic, and inflammatory pathways, including glomerular hyperfiltration, podocyte stress, lipotoxicity, insulin resistance, activation of the renin-angiotensin system, and chronic low-grade inflammation. Given the rise in the prevalence of obesity and kidney disease driven by obesity as a primary risk factor, there is a critical need to understand emerging treatment options, including novel incretin-based therapies, to prevent disease progression and decrease cardiovascular burden, which is the leading cause of morbidity and mortality in these patients. We aim to review current treatment standards and discuss novel developments in the pathophysiology, diagnosis, outcome prediction, and management of obesity as a risk factor for kidney injury and CKD.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Mashayekhi M, Qing J, Heidari-Bateni G, et al. Risk factor obesity: treatment standard. Nephrol Dial Transplant. 2026. PMID: 42446420. doi:10.1093/ndt/gfag164

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。